The use of inferior vena cava filters in pediatric patients for pulmonary embolus prophylaxis

To report our experience with inferior vena cava (IVC) filters in pediatric patients. Over a 19-month period, eight low-profile percutaneously introducible IVC filters were placed in four male and four female patients aged 6-16 years (mean 11 years). Indications were contraindication to heparin in s...

Full description

Saved in:
Bibliographic Details
Published inCardiovascular and interventional radiology Vol. 19; no. 6; p. 401
Main Authors Reed, R A, Teitelbaum, G P, Stanley, P, Mazer, M J, Tonkin, I L, Rollins, N K
Format Journal Article
LanguageEnglish
Published United States 01.11.1996
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:To report our experience with inferior vena cava (IVC) filters in pediatric patients. Over a 19-month period, eight low-profile percutaneously introducible IVC filters were placed in four male and four female patients aged 6-16 years (mean 11 years). Indications were contraindication to heparin in six patients, anticoagulation failure in one, and idiopathic infrarenal IVC thrombosis in one. Six of the eight devices placed were titanium Greenfield filters. One LGM and one Bird's Nest filter were also placed. Two of the filters were introduced via the right internal jugular vein by cutdown, and the remainder were placed percutaneously via the right internal jugular vein or the right common femoral vein. Patients received follow-up abdominal radiographs from 2 to 13 months after IVC filter placement. All filters were inserted successfully without complication. Three of the patients died during the follow-up period: two due to underlying brain tumors at 2 and 12 months and a third at 6 weeks due to progressive idiopathic renal vein and IVC thrombosis. The remaining five patients were all alive and well at follow-up without evidence of IVC thrombosis, pulmonary emboli, or filter migration. IVC filter placement using available devices for percutaneous delivery is technically feasible, safe, and effective in children.
ISSN:0174-1551
DOI:10.1007/bf02577627